{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-010223","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2024-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.821720+00:00","generated_at":"2026-05-31T15:56:22.036376+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ProMIS reports positive Phase 1a data for PMN310 in Alzheimer's","bullets":["PMN310 well-tolerated across four SAD cohorts (2.5-20 mg/kg); no treatment-emergent SAEs.","CSF levels dose-proportional at days 3 and 29; lowest dose >100-fold molar excess over expected oligomers.","CSF half-life ~25 days, supportive of monthly dosing.","Company plans to initiate Phase 1b in Alzheimer's patients in H2 2024.","Full dataset to be presented at a medical meeting in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-010223","json":"https://secwatch.observer/filing/0001558370-24-010223.json","markdown":"https://secwatch.observer/filing/0001558370-24-010223.md","text":"https://secwatch.observer/filing/0001558370-24-010223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000155837024010223/0001558370-24-010223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000155837024010223/pmn-20240726x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:56:22.036376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}